Omicron-adapted vaccines might require longer follow-up to reveal true benefits

Tang, Lu; Zhang, Ruihua; Cui, Miao; Hong, Peng

doi:10.1016/s2666-5247(22)00292-0

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continuously emerging SARS-CoV-2 Omicron sublineages with drifting antigens and numerous and often unique spike protein amino acid changes emphasize the importance of eliciting a breadth of neutralizing antibodies to confer protection against current and future variants; choice of vaccine antigens is critical to achieving this goal [ 27 , 28 ]. A bivalent COVID-19 vaccine encoding the ancestral and contemporary antigens with improved sequence match to the spike protein of circulating strains may elicit broader protection against both circulating strains and potential new variants that are antigenically distinct from the original monovalent BNT162b2 antigen [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds

Usdan,

Patel,

Rodriguez

et al. 2023

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Protection against contemporary SARS-CoV-2 variants requires sequence-adapted vaccines. Methods In this ongoing phase 2/3 trial, 12−17-year-olds (n=108), 18−55-year-olds (n=313), and >55-year-olds (n=306) who previously received 3 original BNT162b2 30-µg doses, received a fourth dose (second booster) of 30-µg bivalent original/Omicron-BA.4/BA.5-adapted BNT162b2 (BNT162b2-Omi.BA.4/BA.5). For comparisons with original BNT162b2, participants were selected from another phase 3 trial. Immunologic superiority 1-month post-vaccination, with respect to 50% neutralizing titers (GMR lower bound [LB] 2-sided 95%CI >1), and noninferiority with respect to seroresponse rates (rate-difference LB 2-sided 95%CI >−5%), for Omicron BA.4/BA.5 were assessed in >55-year-olds versus original BNT162b2 as a second booster. Noninferiority with respect to neutralizing titer level (GMR LB 2-sided 95%CI >0.67) and seroresponse rate (rate-difference LB 2-sided 95%CI >−10%) of Omicron BA.4/BA.5 immune response for BNT162b2-Omi.BA.4/BA.5 in 18‒55-year-olds versus >55-year-olds was assessed. Results One-month post-vaccination in >55-year-olds, model-adjusted GMR of Omicron BA.4/BA.5 neutralizing titers for the BNT162b2-Omi.BA.4/BA.5 versus BNT162b2 group (2.91; 95%CI 2.45−3.44) demonstrated superiority of BNT162b2-Omi.BA.4/BA.5. Adjusted difference in percentages of >55-year-olds with seroresponse (26.77%; 95%CI 19.59−33.95) showed noninferiority of BNT162b2-Omi.BA.4/BA.5 to BNT162b2. Noninferiority of BNT162b2-Omi.BA.4/BA.5 in 18‒55-year-olds to >55-year-olds was met for model-adjusted GMR and seroresponse. GMTs in 12−17-year-olds increased from baseline to 1-month post-vaccination. The BNT162b2-Omi.BA.4/BA.5 safety profile was similar to booster doses of bivalent Omicron BA.1-modified BNT162b2 and original BNT162b2 reported in previous studies. Conclusions Based on immunogenicity and safety data up to 1-month post-vaccination in participants who previously received 3 original BNT162b2 doses, a BNT162b2-Omi.BA.4/BA.5 30 µg booster has a favorable benefit-risk profile. Clinical trial registration NCT05472038

show abstract

Section: Discussionmentioning

confidence: 99%

A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds

Usdan,

Patel,

Rodriguez

et al. 2023

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

Comparative analysis of eleven SARS-CoV-2 immunoassays and neutralisation data: time to enhance standardisation and correlation of protection

Cabrera-Alvargonzalez,

Davina-Nunez,

Rey-Cao

et al. 2024

Infectious Diseases

View full text Add to dashboard Cite

Crisis Communication and Vaccination Acceptance During COVID-19 Pandemic: A Correlational Study

Serradj

2023

Illness, Crisis & Loss

View full text Add to dashboard Cite

This study investigates the relationship between government communication and vaccination acceptance during the COVID-19 pandemic. A questionnaire was distributed, covering acceptability, government communication visibility, clarity, and efficacy, factors influencing vaccination decisions, and government responsiveness. Correlation analyses and regression were conducted. Results showed significant correlations between communication clarity and various variables, including communication's role in vaccination decisions, trust in government communication, and encountered obstacles. Vaccination acceptance was positively associated with communication clarity and perceived vaccination benefits, while government responsiveness was also positively linked to acceptance. Findings emphasize the importance of clear and trustworthy government communication in promoting vaccination acceptance during public health crises.

show abstract

Omicron-adapted vaccines might require longer follow-up to reveal true benefits

Cited by 3 publications

References 12 publications

A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds

A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds

Comparative analysis of eleven SARS-CoV-2 immunoassays and neutralisation data: time to enhance standardisation and correlation of protection

Crisis Communication and Vaccination Acceptance During COVID-19 Pandemic: A Correlational Study

Contact Info

Product

Resources

About